TrialPharmacology research & perspectives2021

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.

Hong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.